The ORR was 61% (78 of 127; 95% CI: 52%–70) for those with EGFR T790M–mutant NSCLC, and the median duration of progression-free survival (PFS) was 9.6 months (95% CI: 8.3 to not reached; Jänne et al., 2015). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.